IPO
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2018 as well as operative highlights.
Evotec SE announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities.
Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
Brings total raised in the Series E round to $276 million
Spherix’s investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%. The recently announced asset-purchase agreement of CBM BioPharma extends pipeline promise.
Zomedica Pharmaceuticals Corp. announced that it has completed its second tranche closing of Series 1 Preferred Shares with the issuance of 7 Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share for a total purchase price of $7,000,000.
Global Blood Therapeutics, Inc. announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the company’s common stock with a per share exercise price of $60.78 and restricted stock units for an aggregate of 96,700 shares of the company’s common stock.
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
PRESS RELEASES